PATENT CLAIM ANALYSIS

Application Number: 15951848
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "056000"]

Abstract:
The present invention relates to the use of heparin derivatives for the prevention and/or treatment of cancer and/or cancer metastasis. The heparin derivatives are substantially 2-O and/or 6-O desulphated heparins which function as inhibitors of galectin-3 activity.

Claim (Index 31):
A method of inhibiting, preventing and/or treating tumour angiogenesis, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a heparin derivative, or a pharmaceutically acceptable salt thereof, wherein the heparin derivative comprises one or more disaccharide units comprising a uronate moiety linked to a glucosamine moiety, and wherein:\n (i) the 2-O atom of the uronate moiety and/or the 6-O atom of the glucosamine moiety are substantially desulphated; and (ii) the heparin derivative exhibits less than 1% of the Anti-Factor Xa activity of unmodified porcine intestinal mucosal heparin.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 91.0
- Lexical Diversity: 1.34483
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14440005', '11882978', '11314736', '12227630', '13304292']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7753265110193216
- 35 USC 102 Novelty (BERT): 0.527250726848766
- Combined Prediction Score: 0.750518932602266
- Mean Citation Score: 281.08527999999995
- Max Citation Score: 341.1478600000001
- Similarity Product: 218.11107355669984

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test